A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Rupatadine (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 05 Jan 2018 Status changed from recruiting to discontinued.
- 09 Sep 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2017.
- 09 Sep 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Jun 2017.